Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 25 01 2019
accepted: 01 05 2019
pubmed: 3 5 2019
medline: 4 12 2019
entrez: 4 5 2019
Statut: ppublish

Résumé

Surgery is the treatment of choice for non-functioning pituitary macroadenomas (NFPAs). In cases of postoperative remnant growth or tumor recurrence, radiotherapy (RT) can be considered. The role of RT in the postoperative management of NFPAs is still debated. The main arguments against routine use of RT are the lack of randomized controlled trials, the use of clinically irrelevant endpoints in most studies on RT, the benign character of the condition, the potential for side effects of RT, and the option to apply RT at a later stage. However, because of its excellent efficacy in inhibiting tumor growth, reducing tumor volume and improving any existing visual defects, and as its side effects seem to be limited compared to the benefits provided, RT keeps a place in the management of NFPAs when a tumor remnant persists, particularly if it is invasive and displays high proliferation markers, if surveillance shows a relevant increase in tumor volume or if the tumor is close to the optic chiasm. The size of the remnant, its vicinity with the optic pathways, and the potential risk to healthy surrounding tissues need to be considered when deciding on an RT procedure.

Identifiants

pubmed: 31048560
doi: 10.1530/EJE-19-0058
pii: EJE-19-0058.R1
doi:
pii:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

D1-D13

Auteurs

Philippe Chanson (P)

Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin Bicêtre, France.
Univ Paris-Sud, Faculté de Médecine Paris-Sud, Univ Paris-Saclay, Unité Mixte de Recherche-S1185, Le Kremlin Bicêtre, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), U1185, Le Kremlin Bicêtre, France.

Alexandre Dormoy (A)

Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin Bicêtre, France.

Olaf M Dekkers (OM)

Departments of Clinical Epidemiology and Clinical Endocrinology, Leiden University Medical Centre, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH